Antibacterial Prophylaxis in Patients with Neutropenia

Authors:
Brahm H. Segal From the Division of Infectious Diseases, Roswell Park Cancer Institute, Buffalo, New York, and Immunocompromised Host Infectious Diseases Program, University of Nebraska Medical Center, Omaha, Nebraska.

Search for other papers by Brahm H. Segal in
Current site
Google Scholar
PubMed Close
 MD
and
Alison G. Freifeld From the Division of Infectious Diseases, Roswell Park Cancer Institute, Buffalo, New York, and Immunocompromised Host Infectious Diseases Program, University of Nebraska Medical Center, Omaha, Nebraska.

Search for other papers by Alison G. Freifeld in
Current site
Google Scholar
PubMed Close
 MD
Volume/Issue:
Volume 5: Issue 2
Online Publication Date:
Feb 2007
DOI:
https://doi.org/10.6004/jnccn.2007.0023
Full access

Patients with cancer and chemotherapy-induced neutropenia are at risk for severe bacterial infections. This risk is not uniform among all cancer patients but is dependent primarily on the depth and duration of neutropenia and the type of underlying disease. Accordingly, the decision whether to use antibacterial prophylaxis to prevent serious infections in these patients requires a balance between expected benefit and the risks for infection, adverse drug-related events, and emergence of antibiotic resistance. Although antibacterial prophylaxis has the potential to benefit all patients with chemotherapy-induced neutropenia, the benefit regarding reduction in documented infections has been firmly established only in patients with neutropenia expected to exceed 7 days. A recent meta-analysis showed enhanced survival in patients receiving antibacterial prophylaxis during neutropenia; most patients enrolled in the analyzed trials had a hematologic malignancy. Among patients with neutropenia at lower risk for infectious complications (a category that includes most patients with solid tumor malignancies), the main benefit of antibacterial prophylaxis relates to a reduction in fever rather than documented infections. The authors advise quinolone prophylaxis (levofloxacin is preferred), in patients with an expected duration of neutropenia (absolute neutrophil count < 1000/μL) of more than 7 days. Trimethoprim-sulfamethoxazole should be used in patients at risk for Pneumocystis jiroveci (formerly P carinii), such as childhood acute lymphoblastic leukemia. In patients with neutropenia expected to last 7 days or less and not receiving immunosuppressive regimens (e.g., systemic corticosteroids), the authors recommend no initial prophylaxis. However, if such patients develop fever during neutropenia, they should be considered for outpatient empiric therapy with an oral quinolone–containing regimen if they meet criteria for low risk for complications.

Correspondence: Brahm H. Segal, MD, Division of Infectious Diseases, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263. E-mail: brahm.segal@roswellpark.org
  • Collapse
  • Expand
Print ISSN:
1540-1405
Online ISSN:
1540-1413
Publisher:
National Comprehensive Cancer Network
Cover Journal of the National Comprehensive Cancer Network
  • 1.

    Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 2004;100:228–237.

  • 2.

    Lyman GH, Morrison VA, Dale DC et al.. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. Leuk Lymphoma 2003;44:2069–2076.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Lyman GH, Delgado DJ. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer 2003;98:2402–2409.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Maher DW, Lieschke GJ, Green M et al.. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Ann Intern Med 1994;121:492–501.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Cullen M, Steven N, Billingham L et al.. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005;353:988–998.

  • 6.

    Lyman GH, Kuderer NM, Djulbegovic B. Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am J Med 2002;112:406–411.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Hann I, Viscoli C, Paesmans M et al.. A comparison of outcome from febrile neutropenic episodes in children compared with adults: results from four EORTC studies. International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). Br J Haematol 1997;99:580–588.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Engelhard D, Elishoov H, Or R et al.. Cytosine arabinoside as a major risk factor for Streptococcus viridans septicemia following bone marrow transplantation: a 5-year prospective study. Bone Marrow Transplant 1995;16:565–570.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Bochud PY, Calandra T, Francioli P. Bacteremia due to viridans streptococci in neutropenic patients: a review. Am J Med 1994;97:256–264.

  • 10.

    Rossetti F, Cesaro S, Putti MC, Zanesco L. High-dose cytosine arabinoside and viridans streptococcus sepsis in children with leukemia. Pediatr Hematol Oncol 1995;12:387–292.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Bertz H, Auner HW, Weissinger F et al.. Antimicrobial therapy of febrile complications after high-dose chemo-/radiotherapy and autologous hematopoietic stem cell transplantation—guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003;82(suppl 2):S167–174.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Bow EJ, Loewen R, Cheang MS et al.. Cytotoxic therapy-induced D-xylose malabsorption and invasive infection during remission-induction therapy for acute myeloid leukemia in adults. J Clin Oncol 1997;15:2254–2261.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Schimpff S, Satterlee W, Young VM, Serpick A. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 1971;284:1061–1065.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Zinner SH. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis 1999;29:490–494.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 2003;36:1103–1110.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Gonzalez-Barca E, Fernandez-Sevilla A, Carratala J et al.. Prospective study of 288 episodes of bacteremia in neutropenic cancer patients in a single institution. Eur J Clin Microbiol Infect Dis 1996;15:291–296.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Hughes WT, Armstrong D, Bodey GP et al.. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730–751.

  • 18.

    Centers for Disease Control and Prevention, Infectious Diseases Society of America, American Society of Blood and Marrow Transplantation. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 2000;6:659–713,715,717–727.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Penack O, Beinert T, Buchheidt D et al.. Management of sepsis in neutropenia: guidelines of the infectious diseases working party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2006;85:424–433.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Tamura K. Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group. Int J Antimicrob Agents 2005;26(Suppl 2):Sl23–127.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Freifeld AG, Baden LR, Brown AE et al.. The NCCN fever and neutropenia clinical practice guidelines in oncology, version 1, 2005. Available at: http://www.nccn.org/physician_gls/index.html. Accessed December 18, 2006.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Bucaneve G, Micozzi A, Menichetti F et al.. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005;353:977–987.

  • 23.

    Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005;142:979–995.

  • 24.

    Storring RA, Jameson B, McElwain TJ, Wiltshaw E. Oral nonabsorbed antibiotics prevent infection in acute non-lymphoblastic leukaemia. Lancet 1977;2:837–840.

  • 25.

    Hahn DM, Schimpff SC, Fortner CL et al.. Infection in acute leukemia patients receiving oral nonabsorbable antibiotics. Antimicrob Agents Chemother 1978;13:958–964.

  • 26.

    Verhoef J. Prevention of infections in the neutropenic patient. Clin Infect Dis 1993;17(suppl 2):S359–367.

  • 27.

    Hughes WT, Kuhn S, Chaudhary S et al.. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 1977;297:1419–1426.

  • 28.

    van de Wetering MD, de Witte MA, Kremer LC et al.. Efficacy of oral prophylactic antibiotics in neutropenic afebrile oncology patients: a systematic review of randomised controlled trials. Eur J Cancer 2005;41:1372–1382.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29.

    Lew MA, Kehoe K, Ritz J et al.. Ciprofloxacin versus trimethoprim/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: a randomized, controlled trial. J Clin Oncol 1995;13:239–250.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30.

    Bow EJ, Rayner E, Louie TJ. Comparison of norfloxacin with cotrimoxazole for infection prophylaxis in acute leukemia. The trade-off for reduced gram-negative sepsis. Am J Med 1988;84:847–854.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31.

    Engels EA, Lau J, Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 1998;16:1179–1187.

  • 32.

    Imrie KR, Prince HM, Couture F et al.. Effect of antimicrobial prophylaxis on hematopoietic recovery following autologous bone marrow transplantation: ciprofloxacin versus co-trimoxazole. Bone Marrow Transplant 1995;15:267–270.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33.

    Sepkowitz KA. Pneumocystis carinii pneumonia in patients without AIDS. Clin Infect Dis 1993;17(suppl 2):S416–422.

  • 34.

    Sepkowitz KA, Brown AE, Armstrong D. Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome. More patients, same risk [editorial]. Arch Intern Med 1995;155:1125–1128.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 35.

    Sepkowitz KA, Brown AE, Telzak EE et al.. Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA 1992;267:832–837.

  • 36.

    Kern WV, Andriof E, Oethinger M et al.. Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother 1994;38:681–687.

  • 37.

    Ito JI, Tegtmeier BR, O'Donnell MR. Antibacterial prophylaxis in patients with cancer and neutropenia. N Engl J Med 2006;354:90–94.

  • 38.

    Spanik S, Trupl J, Ilavska I et al.. Bacteremia and fungemia occurring during antimicrobial prophylaxis with ofloxacin in cancer patients: risk factors, etiology and outcome. J Chemother 1996;8:387–393.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 39.

    Gomez L, Garau J, Estrada C et al.. Ciprofloxacin prophylaxis in patients with acute leukemia and granulocytopenia in an area with a high prevalence of ciprofloxacin-resistant Escherichia coli. Cancer 2003;97:419–424.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 40.

    Martino R, Subira M, Altes A et al.. Effect of discontinuing prophylaxis with norfloxacin in patients with hematologic malignancies and severe neutropenia. A matched case-control study of the effect on infectious morbidity. Acta Haematol 1998;99:206–211.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 41.

    Filing 1,5, Bodey GP, Keefe BH. Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Cliii Infect Dis 1992;14:1201–1207.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 42.

    Reduction of fever and streptococcal bacteremia in granulocytopenic patients with cancer. A trial of oral penicillin V or placebo combined with pefloxacin. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. JAMA 1994;272:1183–1189.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 43.

    Bow EJ, Mandell LA, Louie TJ et al.. Quinolone-based antibacterial chemoprophylaxis in neutropenic patients: effect of augmented grampositive activity on infectious morbidity. National Cancer Institute of Canada Clinical Trials. Ann Intern Med 1996;125:183–190.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 44.

    Cruciani M, Malena M, Bosco O et al.. Reappraisal with meta-analysis of the addition of Gram-positive prophylaxis to fluoroquinolone in neutropenic patients. J Clin Oncol 2003;21:4127–4137.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 45.

    Bow EJ, Loewen R, Vaughan D. Reduced requirement for antibiotic therapy targeting gram-negative organisms in febrile, neutropenic patients with cancer who are receiving antibacterial chemoprophylaxis with oral quinolones. Clin Infect Dis 1995;20:907–912.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 46.

    Muto CA, Jernigan JA, Ostrowsky BE et al.. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. Infect Control Hosp Epidemiol 2003;24:362–386.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 47.

    Centers for Disease Control and Prevention (CDC). Vancomycin-resistant Staphylococcus aureus—Pennsylvania, 2002. MMWR Morbid Mortal Wkly Rep 2002;51:902.

  • 48.

    Centers for Disease Control and Prevention (CDC). Staphylococcus aureus resistant to vancomycin—United States, 2002. MMWR Morbid Mortal Wkly Rep 2002;51:565–567.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 49.

    McDonald LC, Killgore GE, Thompson A et al.. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005;353:2433–2441.

  • 50.

    Loo VG, Poirier L, Miller MA et al.. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353:2442–2449.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 51.

    Bartlett JG, Perl TM. The new Clostridium difficile—what does it mean? N Engl J Med 2005;353:2503–2505.

  • 52.

    Almyroudis NG, Segal BH. Antibacterial prophylaxis in patients with cancer and neutropenia. N Engl J Med 2006;354:90–94.

  • 53.

    Freifeld AG, Sepkowitt KA, Martino P et al.. Antibacterial prophylaxis in patients with cancer and neutropenia [letterL N EngI J Med 2006;354:90–94.

  • 54.

    Baden LR. Prophylactic antimicrobial agents and the importance of fitness. N Engl J Med 2005;353:1052–1054.

  • 55.

    MacDougall C, Powell JP, Johnson CK et al.. Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals. Clin Infect Dis 2005;41:435–440.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 56.

    Gasink LB, Fishman NO, Weiner MG et al.. Fluoroquinolone-resistant Pseudomonas aeruginosa: assessment of risk factors and clinical impact. Am J Med 2006;119:526 (e19–25).

Copyright:
Copyright © 2007 by the National Comprehensive Cancer Network
Page Numbers:
8
Article Category:
Research Article
Received:
27 Sep 2006
Accepted:
27 Oct 2006
Print Publication Date:
01 Feb 2007
Online Publication Date:
Feb 2007
Keywords:
Neutropenia; quinolone; TMP-STX; fever; prophylaxis; empirical therapy

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1422 705 94
PDF Downloads 897 245 31
EPUB Downloads 0 0 0